Provided by Tiger Fintech (Singapore) Pte. Ltd.

Blueprint Medicines

83.41
-0.7700-0.91%
Post-market: 85.492.08+2.49%18:17 EDT
Volume:919.99K
Turnover:77.50M
Market Cap:5.33B
PE:-78.15
High:85.41
Open:84.50
Low:83.27
Close:84.18
Loading ...

Stifel Nicolaus Sticks to Its Buy Rating for Blueprint Medicines (BPMC)

TIPRANKS
·
07 Jan

Blueprint Medicines Price Target Maintained With a $140.00/Share by Stephens & Co.

Dow Jones
·
02 Jan

Blueprint Medicines (NASDAQ:BPMC investor three-year losses grow to 18% as the stock sheds US$334m this past week

Simply Wall St.
·
24 Dec 2024

Blueprint Medicines Price Target Maintained With a $125.00/Share by JMP Securities

Dow Jones
·
10 Dec 2024

Blueprint Medicines: A Promising Investment with Innovative Treatments and Strong Financial Position

TIPRANKS
·
09 Dec 2024

Blueprint Medicines (BPMC) Up 8.7% Since Last Earnings Report: Can It Continue?

Zacks
·
30 Nov 2024

Needham adds Axsome to Conviction List, removes Blueprint

TIPRANKS
·
21 Nov 2024

Blueprint Medicines Price Target Maintained With a $125.00/Share by JMP Securities

Dow Jones
·
19 Nov 2024

Blueprint Medicines Corp : Raymond James Raises Target Price to $130 From $125

THOMSON REUTERS
·
18 Nov 2024

TD Cowen Reaffirms Their Buy Rating on Blueprint Medicines (BPMC)

TIPRANKS
·
15 Nov 2024

Blueprint Medicines Price Target Maintained With a $135.00/Share by Needham

Dow Jones
·
15 Nov 2024

Blueprint Medicines’ Promising Pipeline Developments Support Buy Rating

TIPRANKS
·
15 Nov 2024

Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst

Benzinga
·
15 Nov 2024

JPMorgan Initiates Blueprint Medicines at Overweight With $126 Price Target

MT Newswires Live
·
14 Nov 2024

Blueprint Medicines initiated with an Overweight at JPMorgan

TIPRANKS
·
14 Nov 2024

Blueprint Medicines Corp : JP Morgan Initiates Coverage With Overweight Rating; Target Price $126

THOMSON REUTERS
·
14 Nov 2024

Stock Track | Blueprint Medicines Soars on Positive Spillover from Competitor's Data

Stock Track
·
06 Nov 2024

Cogent data has positive read-through to Blueprint, says Barclays

TIPRANKS
·
06 Nov 2024

Mixed Efficacy and Safety Profiles Lead to Hold Rating for Blueprint Medicines and Cogent Biosciences

TIPRANKS
·
06 Nov 2024

Blueprint should rally on today’s Cogent data, says Oppenheimer

TIPRANKS
·
06 Nov 2024